Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss

Alison J. Dawson¹, Eric S. Kilpatrick², Anne-Marie Coady³, Abeer M. M. Elshewehy⁴, Youssra Dakrouy⁴, Lina Ahmed⁴, Stephen L. Atkin⁴* and Thozhukat Sathyapalan¹

Abstract

Background: Evidence suggests that endocannabinoid system activation through the cannabinoid receptor 1 (CB1) is associated with enhanced liver injury, and CB1 antagonism may be beneficial. The aim of this study was to determine the impact of rimonabant (CB1 antagonist) on alanine aminotransferase (ALT), a hepatocellular injury marker, and a hepatic inflammatory cytokine profile.

Methods: Post hoc review of 2 studies involving 50 obese women with PCOS and well matched for weight, randomised to weight reducing therapy; rimonabant (20 mg od) or orlistat (120 mg tds), or to insulin sensitising therapy metformin, (500 mg tds), or pioglitazone (45 mg od). No subject had non-alcoholic fatty liver disease (NAFLD).

Results: Treatment with rimonabant for 12 weeks reduced both ALT and weight (p < 0.01), and there was a negative correlation between Δ ALT and Δ HOMA-IR (p < 0.001), but not between Δ ALT and Δ weight. There was a significant reduction of weight with orlistat (p < 0.01); however, orlistat, metformin and pioglitazone had no effect on ALT. The free androgen index fell in all groups (p < 0.05). The inflammatory marker hs-CRP was reduced by pioglitazone (p < 0.001) alone and did not correlate with changes in ALT. The inflammatory cytokine profile for IL-1β, IL-6, IL-7, IL-10, IL12, TNF-α, MCP-1 and INF-γ did not differ between groups. None of the interventions had an effect on biological variability of ALT.

Conclusion: Rimonabant through CB1 receptor blockade decreased serum ALT that was independent of weight loss and hepatic inflammatory markers in obese women with PCOS without NAFLD.

Trial registration: ISRCTN58369615 (February 2007; retrospectively registered) ISRCTN75758249 (October 2007; retrospectively registered).

Keywords: Alt, Rimonabant, Polycystic ovarian syndrome, Nafld

Background

It has been recently shown through in vitro and animal studies that the cannabinoid receptor 1 (CB-1) contributes to liver injury, inflammation and may be involved in the initiation of hepatocellular carcinoma through endocannabinoid system activation [1, 2]. Endogenous cannabinoids (EC) have been shown to be closely related to fatty liver metabolism [3, 4], modulating lipid metabolism and contributing to non-alcoholic fatty liver disease development (NAFLD) through [5] that may be ameliorated by CB1 receptor antagonism with antagonists such as rimonabant [5]. This is of particular importance given that NAFLD is the most common cause of chronic liver disease [6] leading to cirrhosis [7]. Liver enzymes such as alanine aminotransferase (ALT) are commonly used as a serum markers for liver function and may or may not be elevated in NAFLD that can only be confirmed by a liver biopsy, as the.

NAFLD has been reported to be of an increased prevalence in women with polycystic ovarian syndrome.
(PCOS), a condition that is the most common endocrine problem in premenopausal women [6]. Insulin resistance is common in the pathophysiology of PCOS that mechanistically increases hepatic stress and liver damage by increasing fatty acid oxidation [7]. Metformin reduces insulin resistance in PCOS [8] and has been shown to have some benefit in NAFLD [9]. Pioglitazone, another insulin sensitising agent, has also been shown to be beneficial in both PCOS and NAFLD [10, 11]. Medications causing weight loss (orlistat and rimonabant) have also been effective treatments in PCOS [10, 12] and orlistat has shown to improve features of NAFLD [13].

Further clinical studies to investigate the hepatoprotective effect of rimonabant are not possible as the drug was withdrawn from the market because of neuropsychiatric side effects. We hypothesized that direct CB1 antagonism by rimonabant treatment would decrease ALT levels in subjects without NAFLD, would decrease biological variability of ALT and that this would be independent of weight loss. To investigate this we pooled 2 randomised trials focusing on the modulation of insulin resistance in women with PCOS without NAFLD.

**Methods**

We performed a post hoc data analysis on 2 studies performed involving 50 subjects (Clinical trial registrations: ISRCTN75758249, retrospectively registered and ISRCTN58369615, retrospectively registered [10, 12]). The first was a randomized open-label parallel study with metformin and rimonabant in 20 patients with PCOS with a body mass index (BMI) ≥30 kg/m2. The 20 patients were randomized to either metformin 500 mg t.d.s. or rimonabant 20 mg daily. The second study was a randomized open-label parallel study with metformin, pioglitazone and orlistat in 30 patients with PCOS with a body mass index (BMI) ≥30 kg/m2. The 30 patients were randomized comparing treatment with metformin (500 mg three times a day), orlistat (120 mg three times a day) and pioglitazone (45 mg once daily) in hyperandrogenic, anovulatory Caucasian women with PCOS. It can be seen that the four groups were weight matched with a BMI range of 34.2 to 41.0. In both cases the diagnosis of PCOS was based on all three diagnostic criteria of the Rotterdam consensus, namely clinical and biochemical evidence of hyperandrogenaemia (Ferriman–Gallwey score > 8 and FAI > 4, respectively), oligomenorrhea or amenorrhea, and polycystic ovaries on transvaginal ultrasound [10, 12]. As detailed all subjects had a normal liver ultrasound with no evidence of a fatty liver indicative of NAFLD. Subjects had no concurrent illness, were not on any medication for the preceding 6 months and were not planning to conceive. None of the patients had had a successful pregnancy or a miscarriage at least 5 years prior to the study entry. Subjects were advised not to change their lifestyle, including physical activity and dietary habits, during the study period. Non-classical 21-hydroxylase deficiency, hyperprolactinaemia, Cushing’s disease and androgen-secreting tumours were excluded by appropriate tests. Adherence was monitored by counting the returned medication. All patients gave written informed consent. Additional IRB approval was not needed for this post hoc analysis as informed consent from the patients for future analyses on anonymous data had been given at the time of the initial consent procedure.

Randomization was performed using a random number generator. Both studies were approved by the Hull and East Riding Local Research Ethics Committee and both studies have been conducted in accord with the Consolidated Standards for Reporting Trials (CONSORT) 2010 statement [14].

Clinical and biochemical assessments were performed at randomization and at the end of the 3-month period for the first study [10, 12]. For the second biological variability study, clinical and biochemical assessments were performed at each visit on 10 consecutive occasions at 4-day intervals before and 12-weeks after treatment [12].

Methods have been detailed previously [10, 12] but briefly, study bloods and measurements were undertaken after an overnight fast. Fasting venous blood was collected into serum gel and fluoride oxalate tubes. Samples were separated by centrifugation at 2000 g for 15 min at 4°C, and the aliquots stored at −20°C. Serum testosterone was measured on an Architect analyser (Abbott Laboratories, Maidenhead, UK) and SHBG was measured by immunometric assay with fluorescence detection on a DPC Immulite 2000 analyser (Euro/DPC, Llanberis, UK) using the manufacturer’s recommended protocol. The FAI was obtained as the total testosterone × 100/SHBG. Total cholesterol, triglycerides and high-density lipoprotein cholesterol (HDL-C) levels were measured enzymatically using a Synchron LX20 analyser (Beckman-Coulter, High Wycombe, UK). Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald equation. Serum insulin was assayed using a competitive chemiluminescent immunoassay performed on the manufacturer’s DPC Immulite 2000 analyser (Euro/DPC). The analytical sensitivity of the insulin assay was 2 μU/ml, the coefficient of variation was 6%, and there was no stated cross-reactivity with proinsulin. Plasma glucose was measured using the Synchron LX20 analyser (Beckman-Coulter), using the manufacturer's recommended protocol. The coefficient of variation for the assay was 1.2% at a mean glucose value of 94-6 mg/dl (5.3 mmol/l) during the study period. The insulin resistance (IR) was calculated using the homeostasis model assessment (HOMA) method \[HOMA-IR = (\text{insulin} \times \text{glucose})/22.5\].
The Bio-Plex 200 system with HTF (Bio-Rad, Hercules, CA) was used to evaluate the sera and the levels of IL-1β, IL-6, IL-7, IL-10, IL12, TNF-α, MCP-1 and INF-γ and compared to a set of standards that were run simultaneously in the assay [15].

ALT was used specifically in this study to calculate the HAIR score (hypertension, ALT and insulin resistance) that is a predictive model for NASH (area under the receiver operator curve of 0.85) [16, 17]. Given that the mean ALT may not differ, but the biological variability may decrease specifically with weight loss, ALT biological variation was determined by ALT measurement performed at each of 10 consecutive visits at 4-day intervals, before and after 12 weeks treatment. All samples were taken between 8 and 9 am. Clinical assessments were also taken at these visits. Before analysis the samples were thawed thoroughly and mixed. Alanine aminotransferase was measured on the Unicel® DxC 80 analyser (Beckman-Coulter, High Wycombe, UK). Data are reported as mean ± SD. AST and gammaGT were not measured but have not been shown to be any better than ALT in NAFLD.

Statistical analysis
Statistical analysis was performed using SPSS for Windows version 16.0 (SPSS inc). The power of the studies was based on a significant reduction in total testosterone concentration after treatment with metformin [10, 12]. In data where distribution between individuals violated the assumptions of normality when tested using the Kolmogorov-Smirnov test, median values were used and differences calculated by paired Wilcoxon method. Given that these were randomised clinical trials baseline values were not compared or adjusted for [18]. Biovariability data was analysed by calculating analytical, within subject, and between subject variances (SDA2, SDB2, SDC2, respectively) as detailed previously (5,6). Using this technique, analytical variance (SDA2) was calculated from the difference between duplicate results for each specimen (SDA2 = Σd2/2N, where d is the difference between duplicates, and N is the number of paired results). The variance of the first set of duplicate results for each subject on the ten assessment days was used to calculate the average biological intraindividual variance (SDi2) by subtraction of SDA2 from the observed dispersion (equal to SDB2 + SDC2). Subtracting SDA2 from the overall variance of the first set results determined the interindividual variance (SDG2). The intraindividual (SDi) and interindividual (SDG) variations were estimated as square roots of the respective variance component estimates. For all analysis, a two-tailed P < 0.05 was considered to indicate statistical significance.

Results
The patients were weight matched in each group (Table 1) and no patient had a fatty liver on ultrasound or a positive HAIR score (data not shown). Within group analysis showed that rimonabant reduced mean ALT from 30.8 U/l to 24.4 U/l, p < 0.01. There was a significant weight loss from (104.6 vs. 98.4 kg; p < 0.01) and reduction in body mass index (BMI) (36.9 vs. 34.5 kg/m2; p < 0.01) in the rimonabant group. As previously reported, insulin resistance improved in the group treated with rimonabant.

Table 1: Anthropometric and metabolic data

| Parameter         | Metformin n = 20 | P-value | Rimonabant n = 10 | P-value | Orlistat n = 10 | P-value | Pioglitazone n = 10 | P-value |
|-------------------|------------------|---------|-------------------|---------|-----------------|---------|---------------------|---------|
|                   | Baseline         | 12 weeks|                   |         | Baseline        | 12 weeks|                   |         |
| Weight (kg)       | 103.8 ± 3.9      | 0.08    | 104.6 ± 4.6       | <0.01   | 103.1 ± 6.9     | <0.01   | 96.3 ± 4.9          | 0.06    |
| BMI (kg/m²)       | 35.7 ± 1.4       | 0.08    | 36.86 ± 1.0       | <0.01   | 37.4 ± 2.7      | <0.01   | 36.2 ± 1.8          | 0.06    |
| FAI (%)           | 20.5 ± 4.0       | 0.04    | 26.6 ± 6.1        | <0.01   | 16.4 ± 2.4      | 0.01    | 18.1 ± 2.9          | 0.02    |
| ALT (U/L)         | 20.5 ± 2.5       | 0.14    | 30.8 ± 5.1        | <0.01   | 13.2 ± 2.0      | 0.49    | 20.4 ± 7.0          | 0.58    |
| HOMA-IR           | 3.4 ± 0.7        | 0.77    | 4.4 ± 0.5         | 0.05    | 5.0 ± 0.8       | 0.01    | 4.5 ± 0.8           | 0.01    |
| hsCRP (mg/l)      | 4.2 ± 1.7        | 0.9     | 5.6 ± 1.2         | 0.7     | 6.2 ± 2.0       | 0.6     | 7.2 ± 1.8           | 0.01    |
| TC                | 6.0 ± 0.3        | 0.12    | 5.1 ± 0.3         | 0.19    | 5.1 ± 1.2       | 0.6     | 5.0 ± 0.4           | 0.09    |
| LDL-C             | 3.9 ± 0.3        | 0.06    | 3.3 ± 0.3         | 0.21    | 3.1 ± 0.2       | 0.08    | 3.1 ± 0.3           | 0.04    |
| HDL-C             | 1.2 ± 0.2        | 0.7     | 1.2 ± 0.2         | 0.4     | 1.2 ± 0.05      | 0.9     | 1.2 ± 0.06          | 0.08    |
| TG                | 2.0 ± 0.3        | 0.4     | 1.4 ± 0.2         | 0.4     | 1.8 ± 0.02      | 0.8     | 1.4 ± 0.2           | 0.08    |

BMI body mass index, FAI free androgen index, ALT alanine aminotransferase, HOMA-IR homeostasis model assessment of insulin resistance, hsCRP high-sensitivity C-reactive protein

Data are presented as mean ± SD. All serum results are obtained from fasting variables. All variables were normally distributed. To convert values for glucose to milligrams per decilitre, divide by 0.056. To convert values for insulin to picomoles per litre, multiply by 6. To convert values for cholesterol to milligrams per decilitre, divide by 0.0259. To convert values for triglycerides to milligrams per decilitre, divide by 0.0113. To convert values for testosterone to nanograms per decilitre, divide by 0.03467. To convert values for SHBG to micrograms per decilitre, divide by 34.7. TC Total cholesterol, LDL-C, LDL-cholesterol, HDL-C, HDL cholesterol, TG, triglycerides FAI free androgen index
There was no correlation between Δ ALT and weight or BMI in the patients treated with rimonabant.

Neither metformin nor pioglitazone affected Δ ALT, weight or BMI (Table 1). Orlistat did not significantly reduce Δ ALT despite a reduction in their BMI (37.4 ± 2.7 vs. 35.2 ± 2.4) that represented a Δ - 5.7% change (0.8), p < 0.01 after treatment (Table 1). The magnitude of weight loss did not differ between rimonabant or orlistat treatment.

The percentage change from baseline ALT for Rimonabant, Metformin, Orlistat and Pioglitazone were 21%, 12%, 8% and 9% respectively. ANOVA of the percentage change in ALT for Rimonabant, Metformin, Pioglitazone and Orlistat and Tukey’s post hoc analysis showed a significant reduction in ALT with Rimonabant therapy (p < 0.05) alone.

The FAI decreased in all groups with treatment (p < 0.05); ANOVA showed no difference between groups and the FAI did not correlate with ALT.

The intrapatient variation of ALT did not differ before or after rimonabant or metformin treatment both within and between groups (p > 0.05). Neither orlistat nor pioglitazone had any effect on the biological variability of ALT.

The inflammatory marker hs-CRP was significantly decreased by pioglitazone alone (p < 0.01) but not correlate with ALT change. The pro-inflammatory cytokine profile performed between the metformin and rimonabant groups: IL-1β, IL-6, IL-7, IL-10, IL12, TNF-α, MCP-1 and INF-γ did not differ following either treatment (Table 2).

There were no changes in the lipid parameters for each of the treatment arms (Table 1).

These data show that rimonabant reduced the ALT of obese PCOS women while orlistat also led to a significant weight reduction, there was no corresponding fall in ALT suggesting that the effect of rimonabant on ALT was independent of the weight loss effect, and this change in ALT correlated with a reduction in insulin resistance. However, there was a reduction in weight and a reduction insulin resistance for both rimonabant and orlistat therefore it is not clear if their insulin resistance was reduced by rimonabant through CB1 or indirectly through weight loss, though in an animal model rimonabant countered age-induced insulin resistance [19]. An adverse metabolic profile associated with hyperandrogenemia has been correlated to NAFLD in PCOS [20], however whilst all treatments reduced the FAI there was no correlation to changes in ALT, suggesting a hepatic dependent mechanism, and suggesting that the changes seen for rimonabant were independent of its affect on androgen reduction. Similarly, the reduction of the inflammatory marker hsCRP was only seen for pioglitazone and therefore likely modulated by peroxisome proliferator-activated receptor gamma, rather through potential CB1 blockade. There were no changes in the pre-inflammatory hepatic cytokine profile between metformin and rimonabant.

The EC system comprises of CB1 (found mainly in the brain and the peripheral tissues) and CB2 receptors found mainly in the immune and endothelial system [21]. The liver has a low expression of the EC receptor that subsequently becomes up-regulated following liver injury [22]. Recent in vitro and animal data indicates that activation of the EC system through CB1 may enhance liver damage with inflammation and hepatocellular carcinoma initiation [1, 2]. Thus is a novel mediator of liver disease [23]. EC through the CB1 receptors [24] are closely related to fatty liver metabolism [3, 4] and associated with NAFLD by modulating lipid metabolism [5]. These results appear discordant to the large population ADAGIO-lipids trial that showed weight loss and a decrease in ALT with rimonabant [25], and another trial showing weight loss was associated with a reduction in liver fat [26]; however, the first was a specific population with an atherogenic lipid profile and established fatty liver infiltration and the second trial was specifically in metabolic syndrome patients with demonstrable increased liver fat, and neither population was representative of the PCOS subjects here who had a normal liver ultrasound.

Rimonabant, is an N-acylaminopiperidinyl derivative and was the first approved CB1 antagonist for the

### Table 2 Comparison of the pro-inflammatory cytokine profile before and after 12 weeks treatment with metformin or rimonabant

| Parameter | Metformin group (n = 10) | Rimonabant group (n = 10) |
|-----------|--------------------------|----------------------------|
|           | Baseline | 12 weeks | P-value | Baseline | 12 weeks | P-value |
| IL-1β     | 86 ± 56  | 105 ± 89 | 0.17    | 85 ± 77  | 91 ± 91  | 0.32    |
| IL-6      | 12 ± 6   | 13 ± 7   | 0.31    | 17 ± 8   | 18 ± 9   | 0.31    |
| IL-7      | 249 ± 18 | 252 ± 31 | 0.69    | 235 ± 47 | 263 ± 49 | 0.11    |
| IL-10     | 23 ± 32  | 27 ± 30  | 0.29    | 10 ± 6   | 10 ± 6   | 0.92    |
| IL-12     | 203 ± 60 | 223 ± 83 | 0.11    | 201 ± 41 | 207 ± 33 | 0.50    |
| TNF-α     | 7 ± 3    | 8 ± 4    | 0.33    | 9 ± 4    | 9 ± 4    | 0.99    |
| MCP-1     | 294 ± 66 | 298 ± 88 | 0.80    | 279 ± 60 | 307 ± 58 | 0.6     |
| INF-γ     | 30 ± 10  | 30 ± 9   | 0.83    | 30 ± 7   | 36 ± 9   | 0.6     |

No difference in the inflammatory cytokine profile between metformin and rimonabant treated patients

IL: interleukin, TNF: tumour necrosis factor, MCP: monocyte chemotactic protein, INF: interferon

No patient suffered any neuropsychiatric symptoms during rimonabant therapy.
treatment of obesity. However, it was withdrawn from the market due an increase in psychiatric disorders [21]. Animal studies have shown that rimonabant treatment reduce CB1 expression in diet induced obese mice [3, 27] and treatment results in a decrease in steatosis and associated metabolic diseases [28]. In four large human trials, rimonabant reduced weight and reduced liver steatosis and insulin sensitivity [29–31], data in accord with the reduction in ALT seen in this study. ALT did not correlate with weight loss and no change was seen in ALT with weight loss due to orlistat therapy confirming that this was more likely a direct effect of rimonabant rather than an indirect effect through weight loss.

Whilst metformin [32] pioglitazone [9] have been reported to reduce ALT and improve NAFLD neither would have been expected to have an affect on the ALT in normal individuals as found here.

The biological variation of insulin resistance has been demonstrated to be increased in PCOS women compared to controls [33]. If ALT variability was related directly to fluctuation in insulin resistance then it may have been expected that there would have been a reduction with intervention [10]. That the biological variation of ALT was unchanged here suggests it is not dependent on insulin resistance and that other factors, as yet unknown, affect it more. In both studies, metformin did not result in any change in insulin resistance whereas rimonobant, pioglitazone and orlistat all resulted in an improvement in insulin sensitivity; however, as we have noted before the insulin sensitising action of metformin may be lost or reduced as BMI increases [10, 12].

Whilst a total of 50 subjects were included, this is still a small sample for a parallel study, though such a study with rimonabant is no longer possible to conduct. The inclusion of a weight matched normal population would have ideally also been included for each intervention. However, for the reduction in ALT with rimonabant not to be significant, all three other treatments would need to have actively increased ALT.

**Conclusion**

Rimonabant reduced ALT in obese women with PCOS without liver disease independent of weight loss and inflammatory hepatic markers, and the fall in mean ALT correlated to the reduction of insulin resistance, though biological variability was unchanged, data in accord with the increasing evidence from animal and in vitro data of CB1 antagonist benefit in liver disease.

**Abbreviations**

ALT: Alanine aminotransferase; BMI: Body mass index; CB1: Cannabinoid receptor 1; EC: Endogenous cannabinoids; FAI: Free androgen index; HOMA-IR: Insulin resistance; hsCRP: C reactive protein; IL: Interleukin; INF: Interferon; MCP: Monocyte chemotactic protein; NAFLD: Non alcoholic fatty liver disease; PCOS: Polycystic ovary syndrome; TNF: Tumour necrosis factor.

**Acknowledgements**

We would like to thank the staff at Clinical Research Centre, Hull Royal Infirmary for their help in patient recruitment and sample analysis.

**Funding**

This research was funded by the Diabetes Charitable funds, Hull and East Yorkshire Hospitals Trust, UK.

**Availability of data and materials**

All data is available through Dr. Sathyapalan.

**Authors’ contributions**

AJD, AMME, YD, LA, SLA and ESK researched literature and conceived study. TS and SLA were involved in protocol development and gaining ethical approval. AJD, SLA AMC and ESK wrote first draft of manuscript. All reviewers reviewed and edited the manuscript and approved the final version of the manuscript.

**Ethics approval and consent to participate**

The ethics committee of Hull and East Riding approved this study. All patients gave written informed consent. No vulnerable subjects or minors were included in the study.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Department of Diabetes and Endocrinology, University of Hull, Hull, UK. 2Department of Clinical Biochemistry, Sidra Medical and Research Centre, Doha, Qatar. 3Department of Obstetric Ultrasound, Hull & East Yorkshire Women’s & Children’s Hospital, Hull, UK. 4Weill Cornell Medicine Qatar, Research Department, PO Box 24144, Doha, Qatar.

**Received: 24 January 2017 Accepted: 9 July 2017**

**Published online: 14 July 2017**

**References**

1. Mai P, et al. Endocannabinoid system contributes to liver injury and inflammation by activation of bone marrow-derived Monocytes/macrophages in a CB1-dependent manner. J Immunol. 2015;195(7):3390–401.
2. Mukhopadhyay B, et al. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms. Hepatology, 2015;61(5):1615–26.
3. Osei-Hyiaman D, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115(5):1298–305.
4. Jeong WI, et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab. 2008;7(3):227–35.
5. Shi D, et al. Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model. Lipids Health Dis. 2014;13:173.
6. Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol. 2014;20(26):8551–63.
7. Oberlinner C, et al. Alanine-aminotransferase levels predict impaired glucose tolerance in a worksite population. Acta Diabetol. 2010;47(2):161–5.
8. Kolodziejczyk B, et al. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril. 2000;73(6):1149–54.
9. Duseja A, et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol. 2007;6(4):222–6.
10. Cho LW, et al. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol. 2009;70(2):233–7.
11. Belfort R, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–307.
12. Sathyapalan T, et al. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. Clin Endocrinol. 2008;69(6):931–5.
13. Zelber-Sagi S, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4(5):639–44.
14. Moher D, et al. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63(8):e1–37.
15. Dirchwolf M, et al. Immune dysfunction in cirrhosis: distinct cytokines phenotypes according to cirrhosis severity. Cytokine. 2015;77:14–25.
16. Dixon JB, Bhatial PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91–100.
17. Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8(10):661–8.
18. Senn S. Testing for baseline balance in clinical trials. Stat Med. 1994;13(17):1715–26.
19. Lipina C, et al. CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction. Aging Cell. 2016;15(2):325–35.
20. Chen MJ, Ho NN. Hepatic manifestations of women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:119–28.
21. Bergstrom MA, et al. Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant. Drug Metab Dispos. 2011;39(10):1823–32.
22. Siegmund SV, Schwabe RF. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2008;294(2):257–62.
23. Mallat A, Lotersztajn S. Endocannabinoids and liver disease. I. Endocannabinoids and their receptors in the liver. Am J Physiol Gastrointest Liver Physiol. 2008;294(1):9–12.
24. Alsawat KA. The role of endocannabinoids system in fatty liver disease and therapeutic potentials. Saudi J Gastroenterol. 2013;19(4):44–51.
25. Despres JP, et al. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-lipids trial. Arterioscler Thromb Vasc Biol. 2009;29(3):416–23.
26. Bergholm R, et al. CB1(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans. Int J Obes. 2013;37(5):699–703.
27. Jourdan T, et al. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes. 2010;59(4):926–34.
28. Gary-Bobo M, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology. 2007;46(1):122–9.
29. Pi-Sunyer FX, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes. 2000;49(11):2855–60.
30. Jayagopal V, et al. The biological variation of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab. 2002;87(4):1560–2.